Clinical characteristics of mitral valve prolapse patients and controls
| MVP total (n=59) | Controls (n=39) | P value | |
| Clinical characteristics | |||
| Age, years mean (SD) | 55 (15) | 52 (19) | 0.43 |
| Male, n (%) | 29 (49%) | 18 (46%) | 0.77 |
| HR, beats/min mean (SD) | 70 (14) | 61 (9) | <0.001 |
| BSA, m2 mean (SD) | 1.87 (0.22) | 1.80 (0.19) | 0.11 |
| SBP, mm Hg mean (SD) | 125 (15) | 124 (24) | 0.63 |
| HTN, n (%) | 13 (22%) | 5 (13%) | 0.25 |
| DM, n (%) | 0 | 0 | N/A |
| Tob use, n (%) | 0 | 0 | N/A |
| CAD, n (%) | 0 | 0 | N/A |
| Atrial fibrillation, n (%) | 12 (20%) | 0 | 0.009 |
| QRS, ms mean (SD) | 96 (19) | 92 (9) | 0.17 |
| QTc, ms mean (SD) | 437 (33) | 423 (29) | 0.022 |
| Antiarrhythmics (sotalol, flecainide, dofetilide, amiodarone), n (%) | 7 (12%) | 0 | 0.026 |
| Beta-blockers, n (%) | 21 (36%) | 0 | <0.001 |
| Calcium-channel blockers, n (%) | 5 (8%) | 0 | 0.062 |
| Echocardiographic characteristics | |||
| LVEF, % mean (SD) | 62% (7%) | 63% (5%) | 0.42 |
| LVEDVI, mL/m2 mean (SD) | 69 (17) | 58 (10) | 0.001 |
| LVESVI, mL/m2 mean (SD) | 26 (9) | 22 (5) | 0.004 |
| GLS, % (SD) | −19.7 (3.8) | −21 (2.0) | 0.045 |
| Mechanical dispersion, ms mean (SD) | 52 (19) | 42 (10) | 0.005 |
| MR vena contracta width, cm mean (SD) | 0.37 (0.23) | 0.1 (0.04) | <0.001 |
| LV mass index, g/m2 mean (SD) | 91 (21) | 67 (15) | <0.001 |
| RV dilatation, n (%) | 0 | 0 | N/A |
| RV systolic dysfunction, n (%) | 0 | 0 | N/A |
| LA volume (end-systole), mL/m2 mean (SD) | 41 (15) | 28 (8) | <0.001 |
BSA, body surface area; CAD, coronary artery disease; DM, diabetes mellitus; GLS, global longitudinal strain; HR, heart rate; HTN, hypertension; LA, left atrium; LV, left ventricle; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end systolic volume index; MR, mitral regurgitation; N/A, not available; RV, right ventricle; SBP, systolic blood pressure.